Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
5 On Your Side shares 7 simple ways to cut down your energy bill this summer
Recommended
Q&A: Preparing dogs for summertime heat
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
105.22
-0.52 (-0.49%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
27
28
Next >
Nasdaq Futures Rise As Focus Turns To Tesla, Netflix Q2 Prints: Analyst Says Earnings Need Some 'Heavy Lifting' For Sustained Rally
July 19, 2023
Via
Benzinga
Why Novartis Stock Spiked Today
July 18, 2023
A massive share buyback program and an improved outlook powered a mid-single-digit rise in the drugmaker's shares today.
Via
The Motley Fool
Novartis Ag (NVS) Q2 2023 Earnings Call Transcript
July 18, 2023
NVS earnings call for the period ending June 30, 2023.
Via
The Motley Fool
NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories
July 18, 2023
Wall Street Journal
Via
Benzinga
Novartis Puts Up Its Biggest Earnings Growth In Two Years; Shares Pop
July 18, 2023
Novartis put up more than 17.3% growth in its profit, beating quarterly records since June 2021.
Via
Investor's Business Daily
Earnings Preview For Novartis
July 17, 2023
Via
Benzinga
Novartis Q2 Earnings: Company Lifts Outlook, Launches $15B Share Buyback, Maps Out Sandoz Spin-Off
July 18, 2023
Novartis AG (NYSE: NVS) reported Q2 FY23 sales of $13.62 billion, up 7% Y/Y and 9% on constant currency, beating the consensus
Via
Benzinga
Nasdaq, S&P 500 Futures Dip Ahead of Big Bank Earnings, Retail Sales Data: Why This Analyst Stays Cautious About Tech Sector
July 18, 2023
Via
Benzinga
Bank of America, Morgan Stanley And 3 Stocks To Watch Heading Into Tuesday
July 18, 2023
With U.S. stock futures trading slightly lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Drug Maker Novartis Stock Shows Rising Relative Strength
July 17, 2023
Novartis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the preferred 80-plus score.
Via
Investor's Business Daily
MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022
July 17, 2023
MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for...
Via
Benzinga
(NVS) - Analyzing Novartis's Short Interest
July 12, 2023
Via
Benzinga
Why Are BeiGene Shares Trading Lower Today
July 11, 2023
BeiGene Limited (NASDAQ: BGNE) shares are trading lower after the company mutually agreed to
Via
Benzinga
US Court Issues Negative Decision On Novartis' Heart-Failure Drug Patent
July 10, 2023
Swiss pharma giant Novartis AG (NYSE: NVS)
Via
Benzinga
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
July 17, 2023
The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030.
Via
Benzinga
S&P Makes Weekly Advance As Inflation Reaches Lowest Level Since March 2021; Amazon, Microsoft, Alphabet And Major Banks Lead Market Optimism
July 14, 2023
The S&P 500 is closing the week in the green in light of positive inflation data. The index was 2.48% higher on the week ahead of the market close Friday. Other major market indexes also showed an...
Via
Benzinga
Eli Lilly Unveils A Nearly $2 Billion Deal To Leap Ahead In Weight Loss
July 14, 2023
The company is hoping to curb the lean muscle mass loss tied to weight-loss drugs.
Via
Investor's Business Daily
Why Novartis Stock Slipped on Friday
July 07, 2023
A major company product lost a key legal protection.
Via
The Motley Fool
Novartis Earnings Conference Call Is Coming Up, Here's What You Need To Know
July 06, 2023
Via
Benzinga
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
July 13, 2023
An overweight world is hungry for new treatments. For now, two companies own the market.
Via
Investor's Business Daily
3 Penny Stocks to Catapult You Into the Millionaires’ Club
July 13, 2023
These penny stocks can deliver tremendous upside from their depressed range. Wall Street analysts can back it up!
Via
InvestorPlace
Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ: WINT) Is Helping Change That
July 12, 2023
Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology company treating late-stage acute cardiovascular disorders, is advancing its first-in-class drug for serious heart conditions.
Via
Benzinga
3 Biotech Stocks That AI is Loving in July
July 12, 2023
As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential.
Via
InvestorPlace
Bausch + Lomb Expands OTC Eye Care Portfolio, Acquires JNJ's Blink
July 06, 2023
Bausch + Lomb Corporation (NYSE: BLCO) has acquired Johnson & Johnson's (NYSE: JNJ) eye and contact lens drops brand Blink for $106.5 million to bolster its position in over-the-counter (OTC)...
Via
Benzinga
Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire
July 05, 2023
Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis.
Via
Investor's Business Daily
Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment
July 03, 2023
Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting
Via
Benzinga
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
July 01, 2023
Via
Talk Markets
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday
June 30, 2023
The biotech's board is exploring strategic alternatives to boost shareholder value.
Via
The Motley Fool
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories
June 30, 2023
New York Post
Via
Benzinga
Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis
June 30, 2023
Bausch + Lomb Corporation (NYSE: BLCO) has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG (NYSE:
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
27
28
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.